
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results
Revenue of $249.5 million in Q1; decline driven by limited eye care supply Diluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90 Announces agreement to acquire current eye care supplier Pillar5 Pharma Revising …